Matinas BioPharma (NYSEAMERICAN:MTNB) will be issuing its quarterly earnings data on Monday, April 2nd.
Shares of Matinas BioPharma (NYSEAMERICAN MTNB) opened at $0.95 on Monday. The firm has a market capitalization of $96.67, a price-to-earnings ratio of -2.57 and a beta of 0.39. Matinas BioPharma has a 52-week low of $0.83 and a 52-week high of $3.20.
Separately, Maxim Group set a $6.00 target price on Matinas BioPharma and gave the stock a “buy” rating in a research report on Monday, March 19th.
ILLEGAL ACTIVITY WARNING: This news story was reported by Ticker Report and is the property of of Ticker Report. If you are accessing this news story on another publication, it was illegally copied and republished in violation of United States and international trademark and copyright laws. The legal version of this news story can be viewed at https://www.tickerreport.com/banking-finance/3300705/matinas-biopharma-mtnb-scheduled-to-post-quarterly-earnings-on-monday.html.
Matinas BioPharma Holdings, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in identifying and developing therapeutics for the treatment of serious and life-threatening infections. It is engaged in developing a pipeline of product and development candidates, with an initial focus on serious fungal and bacterial infections.
Receive News & Ratings for Matinas BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Matinas BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.